Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Regimen for Children or Adolescents With Mature B-cell NHL or B-AL in China
NCT02405676Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jan 2015
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in mature B-cell non-Hodgkin lymphoma, B cell acute lymphoblastic leukemia (B-ALL), sponsored by Children's Oncology Group. Started Jan 2015; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
mature B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02405676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405676.